Formycon

Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea

1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, on June 28, 2024. Dr. Stefan Glombitza, CEO of Formycon AG, commented: “The FDA approval of FYB203/AHZANTIVEis another key milestone on...

Formycon reports on the results of the annual general meeting

Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and supervisory board by large majority. Supervisory board becomes more international and expands to five members; Colin Bond, Dr Bodo Coldewey and Nicholas Haggar elected as...
Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

+49 89 864667 100